SGP
SpyGlass Pharma, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 9 ▲ 7 insiders buy $66.9M at $16.00
- Mar 9 ▲ SpyGlass Pharma announced positive 12-month results from its Phase 1…
- Mar 9 FDA: SpyGlass Pharma Announces Positive Topline 12-Month Phase…
- Mar 26 ▲ SpyGlass Pharma reported its Q4 and full-year 2025 financial results…
- Aug 14 Raymond James initiates
- Oct 1 ▲ SpyGlass Pharma acquired 100% of Advanced Vision Science, Inc. (AVS)…
- Oct 1 ▲ SpyGlass Pharma acquires AVS from Santen for ~$13M cash, securing co…
- Oct 1 M&A: SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AV…
- Oct 19 FDA: SpyGlass Pharma Announces Positive 4-Year Data From First-…
- Oct 19 ▲ SpyGlass Pharma reported positive interim 4-year data from its first…
- Oct 19 ▲ SpyGlass Pharma announced positive 4-year first-in-human trial resul…
- Nov 11 ▼ Earnings: SGP Q3 2026 Earnings: EPS $-0.73 (-16.1% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
7 insiders bought $66.9M. No open-market sales.
- InstitutionsBULLISH
Q3 2026: 12 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
9 of 10 rate it Buy or better.
- Short sellersSTEADY
Short interest −5.2% to 1.16M shares. 12.1 days to cover, ≈3.5% of shares.
- TrendUPTREND
14% above its 50-day average. New closing high $38.37 on Nov 9.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | ADD | $25.5M |
| Aberdeen Group plc | TRIM | $23.2M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $17.2M |
| STATE STREET CORP | ADD | $4.6M |
| TD ASSET MANAGEMENT INC | ADD | $2.0M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | $1.2M |
| ALPS ADVISORS INC | ADD | $1.2M |
| Russell Investments Group, Ltd. | DOUBLED | $1.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Citigroup MAINTAIN | Buy |
| Nov 13, 2026 | Stifel MAINTAIN | Buy |
| Nov 12, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 21, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Oct 5, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 14, 2026 | Raymond James INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
BASKETT FOREST 10%+ Owner Feb 9, 2026 | CONVERT | 737,962 sh |
Yang Rick 10%+ Owner Feb 9, 2026 | CONVERT | 1,370,168 sh |
BASKETT FOREST 10%+ Owner Feb 9, 2026 | CONVERT | 954,990 sh |
Mathers Edward T 10%+ Owner Feb 9, 2026 | CONVERT | 737,962 sh |
Nielsen Kirk G. Director Feb 9, 2026 | CONVERT | 2,059,573 sh |
Chang Carmen 10%+ Owner Feb 9, 2026 | CONVERT | 1,619,240 sh |
Chang Carmen 10%+ Owner Feb 9, 2026 | CONVERT | 1,370,168 sh |
Chang Carmen 10%+ Owner Feb 9, 2026 | CONVERT | 1,370,168 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
5 filings · 4 press releases · 2 bullish · 0 bearish · 3 neutral- NEUTRAL 8-KNov 12, 2026
SpyGlass Pharma reported Q3 2026 net loss of $24.3M ($0.73/share), wider than the $9.8M loss in Q3…
Monitor Phase 3 enrollment progress and BIM-DRS preliminary data expected in 2027; the AVS acquisition secures commercial manufacturing but adds integration risk. Cash runway through 2028 provides…
- NEUTRAL PRESS-RELEASENov 11, 2026
SpyGlass Pharma reported Q3 2026 net loss of $24.3M ($0.73 per share), wider than the $9.8M loss…
Monitor Phase 3 enrollment milestones and any FDA feedback on the 505(b)(2) NDA pathway for BIM-IOL System. The BIM-DRS FIH preliminary data in 2027 could expand the addressable market beyond…
- BULLISH 8-KOct 19, 2026
SpyGlass Pharma reported positive interim 4-year data from its first-in-human trial of the BIM-IOL…
The 4-year durability and safety data de-risk the BIM-IOL System's Phase 3 program and support a potential 505(b)(2) NDA pathway. Watch for FDA alignment updates and Phase 3 enrollment milestones as…
- BULLISH PRESS RELEASEOct 19, 2026
SpyGlass Pharma announced positive 4-year first-in-human trial results for its Bimatoprost Drug…
The 4-year durability and safety data de-risk the BIM-IOL System's Phase 3 program and support a clear regulatory path. Watch for Phase 3 enrollment completion and FDA meeting outcomes as the next…
All SGP filing & press-release reports (9)
- 8-K reportNov 12, 2026
- PRESS-RELEASE reportNov 11, 2026
- 8-K reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- 8-K reportOct 1, 2026
- PRESS-RELEASE reportOct 1, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMar 26, 2026
- PRESS-RELEASE reportMar 9, 2026